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Abstract
Background Clinical events committees (CEC) are used routinely to adjudicate suspected end-points
in cardiovascular trials, but little information has been published about the various processes used. We
reviewed results of the CEC process used to identify and adjudicate suspected end-point (post-
enrolment) myocardial infarction (MI) in the large Platelet Glycoprotein IIb/IIIa in Unstable Angina:
Receptor Suppression Using Integrilin (Eptifibatide) Therapy (PURSUIT) trial.
Methods The PURSUIT trial randomised 10,948 patients with acute coronary syndromes to receive
eptifibatide or placebo. A central adjudication process was established prospectively to identify all
suspected MIs and adjudicate events based on protocol definitions of MI. Suspected MIs were
identified by systematic review of data collection forms, cardiac enzyme results, and electrocardio-
grams. Two physicians independently reviewed all suspected events. If they disagreed whether a MI
had occurred, a committee of cardiologists adjudicated the case. 
Results The CEC identified 5005 patients with suspected infarction (46%), of which 1415 (28%)
were adjudicated as end-point infarctions. As expected, the process identified more end-point events
than did the site investigators. Absolute and relative treatment effects of eptifibatide were smaller when
using CEC-determined MI rates rather than site investigator-determined rates. The site-investigator
reporting of MI and the CEC assessment of MI disagreed in 20% of the cases reviewed by the CEC.
Conclusions End-point adjudication by a CEC is important, to provide standardised, systematic,
independent, and unbiased assessment of end-points, particularly in trials that span geographic
regions and clinical practice settings. Understanding the CEC process used is important in the
interpretation of trial results and event rates.
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Introduction
MI is an important end-point in clinical trials. The preven-
tion of MI has in fact been the primary treatment effect
assessed in recent trials of antiplatelet and antithrombin
therapies [1–11]. CECs are now commonly used to adju-
dicate suspected end-point events in cardiovascular clini-
cal trials. Limited information has, however, been
published about the classification of the cause of death
[12–16] or the adjudication of nonfatal end-points
[17–24] in these trials. The rates of end-point events can
vary considerably depending on whether committees
merely confirm events reported by investigators or
whether they adjudicate all suspected events identified by
data screening.
In the PURSUIT trial [6], a central, independent CEC sys-
tematically identified and adjudicated all suspected non-
fatal MIs that occurred after enrolment and through a
30-day follow-up. The rationale for CEC adjudication was
the need for a systematic, unbiased, independent, and
standard assessment of this end-point in a large, interna-
tional trial. To understand the role of such a committee,
and to provide recommendations for future efforts, we
reviewed the results of the CEC process used in the
PURSUIT trial to identify and adjudicate suspected end-
point MIs.
Methods
The PURSUIT trial
The PURSUIT trial [6] enrolled 10,948 patients at 726
hospitals in 27 countries from North America, Latin
America, Western Europe, and Eastern Europe. Patients
with acute coronary syndromes without persistent ST-
segment elevation were randomly assigned to placebo or
eptifibatide. The inclusion and exclusion criteria, as well as
treatment regimens, have been published elsewhere [6].
The primary end-point was a composite of death or non-
fatal MI (or reinfarction in patients with MI at enrolment) by
30-day follow-up as adjudicated by the CEC. The com-
posite end-point was also calculated using the site investi-
gator determination of MI from case report forms. We
assessed the incidence of end-point (post-enrolment) MI
among all 10,948 patients enrolled in the PURSUIT trial.
End-point definitions
The definition of end-point MI included a first MI (for
patients without MI at enrolment) or reinfarction (for
patients who had a MI at enrolment), according to clinical,
electrocardiography (ECG), and laboratory criteria (see
Appendix). A MI present at enrolment was not considered
an end-point MI and was not adjudicated by the CEC.
Data collection
Data were collected using standard case report forms.
Additional information collected from all patients included
cardiac enzymes, ECGs (performed at the time of the
qualifying episode, at enrolment, at 24 hours, at first hos-
pital discharge, and at 30-day follow-up), revascularisa-
tion procedure reports, details of ischemic episodes,
clinical complications, medications, and readmission
records. All enzyme values for each patient were
reported; study monitors then verified them against
source documents. Site investigators were asked to
submit supporting documents for patients with suspected
MI, which included discharge summaries and additional
ECGs during the suspected event. Progress notes and
procedure notes were also collected if necessary. An
independent, blinded core laboratory read the specified
ECGs and identified suspected MIs, defined as new Q
waves ≥0.04 s in two contiguous leads. Overall, data for
creatine kinase-myocardial band (CK-MB) were missing
for only 26 patients (0.2%), data for baseline ECG were
missing for 44 patients (0.4%), and data for later ECGs
were missing for 36 patients (0.3%).
Process for event adjudication
The CEC was a group dedicated to event adjudication
within the North American Trial Co-ordinating Centre at
the Duke Clinical Research Institute. The group consisted
of a managing supervisor, clinical coordinators with a
nursing or clinical research background, administrative
assistants, cardiology fellows, and cardiology faculty
members. The CEC helped define clinical end-point
events, helped develop computer algorithms to identify
patients with suspected end-point events from data from
case report forms, worked with monitoring groups to
collect supplemental medical records for event review,
and adjudicated suspected clinical end-point events.
A schematic diagram of the clinical event adjudication
process is shown in Figure 1. Computer algorithms sys-
tematically identified key variables from the database that
could indicate the occurrence of a post-enrolment (end-
point) MI. These variables, which were determined from
clinical expertise and trial experience, included elevated
cardiac enzymes, ECG core laboratory identification of
suspected MI, recurrent ischemic events, urgent revascu-
larisations, or site investigator assessment of a post-enrol-
ment MI. The system was designed for broad identification
of all patients with possible MI after enrolment. A report of
all patients with suspected end-point MI was generated
according to ‘hits’ on the variables already listed.
Each patient with a suspected MI had a clinical folder
prepared by CEC staff at the Duke Clinical Research
Institute. Folders included the case report form and ancil-
lary data forms, discharge summaries, cardiac enzyme
results, ECGs, and a data worksheet that summarised
clinical events, procedures, and cardiac enzyme informa-
tion. Medical records were translated into English if nec-
essary, using physicians literate in the other language
when possible.
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Each case was reviewed independently by two physicians
blinded to treatment in the phase I review. The case was
classified as resolved if the physicians agreed that a MI
had or had not occurred. Cases in which there was dis-
agreement between the two CEC physicians were for-
warded to a second-level (phase II) review for adjudication
by consensus of a committee of faculty cardiologists
(Fig. 1). The committee members were also blinded to
treatment and to the result of the phase I review. Physi-
cians could request additional medical records, if neces-
sary, to adjudicate a suspected event. If additional records
were obtained, the case was re-reviewed to ensure that
decisions were based on similar documents. For quality
assurance, 10% of the cases with agreement by the
phase I physicians were reviewed in a blinded fashion by
the phase II committee to determine whether there were
any systematic inconsistencies with the phase I reviews.
There were no inconsistencies found.
Statistical analysis
Variables were summarised as percentages for dichoto-
mous variables or medians (25th and 75th percentiles) for
continuous variables. The χ2 test was used to calculate
P values.
Results
Overall, 5005 patients with suspected MI after enrolment
(46%) were identified and adjudicated by the CEC.
Table 1 presents the number of patients enrolled and the
number of patients with an end-point MI identified by the
CEC or the site, both or neither, by geographic region.
The proportion of patients with MI adjudicated by the CEC
was similar in North America, Latin America and Western
Europe, but tended to be higher in Eastern Europe.
As expected, because of the rigorous effort by the CEC to
identify all suspected MIs for adjudication, the process
Figure 1
Process for review of suspected clinical events in the PURSUIT trial. ECG, Electrocardiography.
identified more end-point events than did the site investi-
gators (Table 2). Eptifibatide reduced the incidence of
death or MI in the PURSUIT trial by 1.5% (15.7% versus
14.2%; P = 0.042) at 30 days [6]. This benefit was driven
primarily by a reduction in nonfatal MI. We noted smaller
absolute and relative treatment effects when the CEC-
determined MI rates were used compared with the site
investigator-determined rates.
The proportion of patients enrolled who had a suspected
end-point MI ranged from 41% in North America to 50%
in Western Europe (Table 3). Disagreements between the
site investigator and CEC assessment of MI occurred in
9% of all patients enrolled in the trial, or 983 of the 5005
patients with suspected MI adjudicated by the CEC
(20%; Table 3). Of these 983 patients with disagree-
ments, 816 patients had a MI assessed by the CEC but
not by the site investigator, and 167 patients had a MI
identified by site investigators but not by the CEC.
Discussion
The review of the clinical-events classification process in
the current study raises some important issues for clinical
investigators. First, the rates of end-point infarction or re-
infarction were higher than those reported in prior trials of
patients with acute coronary syndromes. Second, the CEC
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Table 2
Efficacy end-points (%) at 30-day follow-up
Eptifibatide* Placebo Absolute Relative Number needed
End-point (n = 4722) (n = 4739) reduction reduction P to treat
Death or infarction
Clinical events committee 14.2 15.7 1.5 9.6 0.042 10.4
Site investigator 8.1 10.0 1.9 19.0 0.0007 5.3
Myocardial infarction
Clinical events committee 12.6 13.6 1.0 7.4 0.137 13.5
Site investigator 6.2 7.8 1.6 20.5 0.002 4.9
* High-dose group only.
Table 3
Disagreements between the site investigator and the clinical events committee
Disagreements (n)
Patients with Patients with 
Region suspected infarction, n (%) disagreement, n (%) Committee no / site yes Committee yes / site no
Eastern Europe 862 (49) 206 (24) 24 182
Latin America 253 (43) 52 (21) 8 44
North America 1779 (41) 356 (20) 57 299
Western Europe 2111 (50) 369 (17) 78 291
Overall 5005 (46) 983 (20) 167 816
Table 1
Identification of end-point myocardial infarctions in the PURSUIT trial
Region CEC MI only Site MI only Both CEC + site MI Neither CEC nor site MI
Eastern Europe (n = 1762) 182 (10.3%) 24 (1.4%) 129 (7.3%) 1427 (81.0%)
Latin America (n = 585) 44 (7.5%) 8 (1.4%) 24 (4.1%) 509 (87.0%)
North America (n = 4358) 299 (6.9%) 57 (1.3%) 205 (4.7%) 3797 (87.1%)
Western Europe (n = 4243) 291 (6.9%) 78 (1.8%) 241 (5.7%) 3633 (85.6%)
Overall (n = 10,948) 816 (7.5%) 167 (1.5%) 599 (5.5%) 9366 (85.6%)
Data presented as n (%). CEC, clinical events committee; MI, myocardial infarction.
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identified more events than the site investigators. Third, the
site investigator and the CEC assessments of MI dis-
agreed for 20% of the patients reviewed by the CEC.
CECs have become an integral aspect of clinical trials of
new therapies for patients with acute coronary syndromes.
The primary function of these committees has been to sys-
tematically adjudicate nonfatal end-points such as MI. The
first large trials in these patients used mortality as the
primary end-point; thus, standardised assessment of
patient outcome was not required [25–27]. More recent
trials, however, have included nonfatal end-points such as
MI, congestive heart failure, stroke, or safety measures as
part of composite clinical end-points. Myocardial infarction
has been considered a ‘hard’ end-point, but its assess-
ment can be as difficult in clinical trials as it is in clinical
practice, because clinical, laboratory, and ECG data may
conflict and physicians often disagree whether a patient
has suffered a MI. An example of this difficulty is the evalu-
ation of small enzyme elevations in patients undergoing
percutaneous coronary intervention [28]. Although these
low-level enzyme elevations are defined as MIs in many
trial protocols, physicians do not consistently consider
them to be infarctions in daily clinical practice and there-
fore may be reluctant to report them as such.
The rates of infarction as adjudicated by the CEC in the
PURSUIT trial were higher than reported in previous trials
of patients with acute coronary syndromes, for several
reasons [1,7,8,29]. First, the PURSUIT trial CEC effort
was more liberal in its identification of possible events.
Committee physicians reviewed events for almost 50% of
the patients in the trial, which is nearly double the per-
centage that underwent adjudication by the same CEC
group in two other trials: Integrilin to Minimize Platelet
Aggregation and Coronary Thrombosis (IMPACT-II) [9],
and Global Use of Strategies to Open Occluded Arteries
in Acute Coronary Syndromes (GUSTO-IIb) [1]. Second,
the definition of MI is evolving and has varied among clini-
cal trials in this patient population. For example, criteria
for MI after bypass surgery in the GUSTO-IIb trial were
more stringent than those in the PURSUIT trial, requiring
two of three criteria to be met (CK or CK-MB fraction ≥5
times the upper limit of normal, two new Q waves, or new
regional wall-motion abnormalities). Finally, more cardiac
enzyme samples were collected per patient in the
PURSUIT trial than in GUSTO-IIb (median [25th, 75th] 4.5
[3,7] versus 3 [1,4]) (RA Harrington, unpublished data).
These factors, particularly the systematic collection of
cardiac enzymes (missing for only 0.2% of the patients),
contributed to a higher ascertainment of MI in the
PURSUIT trial. Trials that rely on investigator-reported MI
probably underestimate the true event rate.
Before implementation of the CEC process, the Interna-
tional Steering Committee agreed on the definitions for MI,
which were based on experience and clinical expertise.
Because of the global nature of the PURSUIT investiga-
tion, attempts were made to model definitions after every-
day clinical practice. The study protocol provided the
end-point definitions, so that the CEC and site investiga-
tors had the same set of criteria to classify MI. Neverthe-
less, the site investigators underreported infarctions.
Similar findings have been noted in prior trials
[1,9,22,23,30,31].
The strategy used to identify suspected infarctions can
affect the proportion of events with disagreements. Some
trials have confirmed events reported only by the investi-
gators [5,7,8,11,29,30], whereas other trials have adjudi-
cated all suspected events identified by systematic
screening of patient data [1–3,9,31,32]. In the first strat-
egy, the CEC event rates will be the same as or lower than
the site investigator-reported rates. In the second, the
CEC event rates may be higher, lower, or the same as the
site investigator-reported rates.
The impact of adjudication of cases from other regions of
the world by physicians based in North America is
unknown. In the current study, however, medical records
were translated to English, physicians fluent in other lan-
guages were used when needed, and the criteria for re-
infarction were based, for the most part, on objective data
such as enzyme and ECG data.
There are several key implications of these findings. The
strategy used to identify and adjudicate end-point events
is one of many factors to be considered when comparing
event rates between clinical studies. During trial planning,
the events classification strategy being considered may
also have an important impact on estimation of event rates
and the calculations of sample size and power. Education
and training of clinical investigators regarding end-point
definitions and ascertainment may help in minimising dif-
ferences between CEC and site investigator assessments
of end-points. Finally, the strategy and rigor of the clinical
event adjudication process used may influence the inter-
pretation of trial results by the clinical and regulatory com-
munities. We believe that CEC adjudication of suspected
nonfatal MI end-point events is important to provide inde-
pendent, unbiased, standard, systematic assessments,
particularly in trials that include broad geographic regions
and different clinical practice settings.
Conclusion
Nonfatal MI, inherently undesirable, is an important clinical
event and an important component of clinical trial end-
points. CEC adjudication of infarction is necessary to
provide standardised, systematic, independent, and unbi-
ased assessments of end-points in clinical investigation. In
the PURSUIT trial, the assessment of infarction by site
investigators versus that of a central CEC disagreed: more
infarctions were identified by the CEC than by the site
investigators. The impact of these findings affects the
comparison of event rates between trials as well as the
design of future trials.
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Appendix: definition for end-point (post-
enrolment) myocardial infarction
Myocardial infarction is defined by either enzyme or elec-
trocardiography (ECG) criteria.
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Enzyme criteria
1. Myocardial infarction (MI) events without documenta-
tion of a prior MI during the admission: creatine kinase-
myocardial band (CK-MB) elevated above the upper
limit of normal (ULN) and ≥3% of total CK. If CK-MB is
unavailable, then total CK > 2 × ULN.
2. MI events with documentation of a prior infarction
during the admission, either before or at enrolment:
If <18 hours since previous MI. Recurrent, severe
ischemic discomfort and new or recurrent ST-segment
elevation ≥0.1 mV in at least two contiguous leads,
either persisting for ≥30 min.
If ≥18 hours since previous MI. Re-elevation of CK-MB
to above the ULN (if prior CK-MB was within normal
range) or > 50% above the prior level (if prior CK-MB
was above the ULN). If CK-MB is unavailable: either
total CK ≥2 × ULN and increased by ≥25%; or
≥1.5 × ULN and increased by ≥200 IU above the pre-
vious value.
3. Periprocedural MI events (occurring during or
< 24 hours after percutaneous coronary intervention):
CK-MB ≥3 × ULN and > 50% above the prior nadir
value. If CK-MB is unavailable, then total CK
≥3 × ULN.
4. Perioperative MI events occurring during or < 36 hours
after bypass surgery): CK-MB ≥5 × ULN (or CK, in the
absence of CK-MB).
ECG criteria
New, significant Q waves or Q-wave equivalents ≥0.04 s
in at least two contiguous leads. If enzyme or ECG data
are unavailable, a MI is considered to have occurred when
there is a preponderance of clinical evidence based on
patient signs, symptoms, ECG changes, and pathological
findings. When enzyme or ECG criteria are available, they
take precedence.
